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Implementation of next-generation DNA sequencing (NGS) technology into routine diagnostic genome care requires strategic
choices. Instead of theoretical discussions on the consequences of such choices, we compared NGS-based diagnostic practices
in eight clinical genetic centers in the Netherlands, based on genetic testing of nine pre-selected patients with cardiomyopathy.
We highlight critical implementation choices, including the speciﬁc contributions of laboratory and medical specialists,
bioinformaticians and researchers to diagnostic genome care, and how these affect interpretation and reporting of variants.
Reported pathogenic mutations were consistent for all but one patient. Of the two centers that were inconsistent in their
diagnosis, one reported to have found ‘no causal variant’, thereby underdiagnosing this patient. The other provided an alternative
diagnosis, identifying another variant as causal than the other centers. Ethical and legal analysis showed that informed consent
procedures in all centers were generally adequate for diagnostic NGS applications that target a limited set of genes, but not for
exome- and genome-based diagnosis. We propose changes to further improve and align these procedures, taking into account
the blurring boundary between diagnostics and research, and speciﬁc counseling options for exome- and genome-based
diagnostics. We conclude that alternative diagnoses may infer a certain level of ‘greediness’ to come to a positive diagnosis
in interpreting sequencing results. Moreover, there is an increasing interdependence of clinic, diagnostics and research
departments for comprehensive diagnostic genome care. Therefore, we invite clinical geneticists, physicians, researchers,
bioinformatics experts and patients to reconsider their role and position in future diagnostic genome care.
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INTRODUCTION
Clinical genetics is changing. Next-generation DNA sequencing (NGS)
is slowly replacing traditional technologies for the diagnosis of genetic
disorders. Instead of gene-by-gene approaches, large sets of genes can
now be addressed in a single test. Moreover, scientiﬁc progress rapidly
expands the group of ‘genetic disorders’. Compared with the previous
‘revolution’ in molecular diagnostics – the introduction of genomic
microarrays as a diagnostic tool 1 – NGS affects many more aspects of
routine diagnostics.
The technology to sequence DNA has been under major develop-
ment over the past 5 years. Excellent reviews have been published on
the basic principles,2 the impact,3 and various applications4 of NGS.
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The steep decrease in run times and costs have turned reading an
individual’s DNA from a multi-annual, multi-laboratory undertaking
into a feasible effort for individual laboratories within a reasonable
time frame. Many individual genomes have now been sequenced,
leading to increasingly comprehensive and speciﬁc maps of human
genetic variation.5–7 Initial assessment of personal genome information
proved highly valuable for disease characterization in individual
patients.8–12 Moreover, exome sequencing revealed causal genetic
mutations for rare congenital syndromes,13–17 intellectual
disability,18,19 autism 20 and schizophrenia.21 Nowadays, NGS tech-
nology is widely used in many areas of clinical genetic research,
including genome-wide association studies for common disease.22–24
Many see the widespread application of NGS in research as a prelude
to its broad acceptance as a diagnostic tool, thereby replacing most
other molecular diagnostic technologies.25–28 Indeed, a number of
pioneering laboratories have already successfully implemented NGS-
based gene panels in a diagnostic setting, but routine application in a
widespread clinical context requires a further decrease in costs and run
times.16,29–31 The latest generation of NGS technologies – in various
stages of development – holds great promise to bridge the cost-
efﬁciency gap.32–34 Yet the biggest challenges are not in the technology
itself, but in aspects that follow application of NGS, such as interpreta-
tion and exchange of data, informing patients appropriately and
increased interdependencies of people involved in genome diagnostics.
Anticipating these developments, many clinical genetic centers
(CGCs) and molecular genetic laboratories are preparing for a
reconﬁguration of their diagnostic process, and in doing so, make
implementation choices based on local requirements and opportu-
nities. Already, many molecular diagnostic laboratories have adopted
NGS as the preferred technology for diagnosing an increasing number
of diseases.16,27,30,31,35–38 In the Netherlands, all CGCs have imple-
mented one or more NGS-based diagnostic applications.39
To study the effect of implementation choices within each center, we
set up a small-scale diagnostic NGS-based testing effort with all eight
CGCs in the Netherlands. All centers received a request for diagnostic
testing of nine patients who had been previously diagnosed for
inherited forms of cardiomyopathy using traditional genetic technol-
ogies. Over the course of 6 months, each laboratory took the samples
through their internal NGS-based testing facilities – which were set up
as routine diagnostics or in a research context – and delivered a full
diagnostic report for each patient. No prior criteria were set for sample
intake, sequencing, data analysis or clinical interpretation; each
laboratory was entirely autonomous in choosing its preferred approach.
All centers drafted short summary reports of each step in the process,
describing the key elements in their approach. The reports, combined
with the diagnostic outcomes and underlying data provide valuable
insights in implementation choices of NGS-based diagnostics infra-
structure and their consequences. The overall aim of this study was
therefore not to develop a standard diagnostic process or data analysis
pipeline, nor to compare centers or platforms on performance or data
quality. Rather, the set up of this study allowed for assessment of the
existing variability in NGS-based diagnostics approaches, providing a
starting point for discussions on future conditions for implementation
procedures in the Netherlands and elsewhere.
MATERIALS AND METHODS
Study design
All CGCs in the Netherlands received DNA samples and medical records from
the same nine patients with cardiomyopathy. The centers were completely
autonomous in applying their individual strategy for providing an NGS-based
diagnosis; no restrictions or guidelines were set to the capture method, quality
of sequencing, analysis tools and settings, or variant reporting. All centers
provided summary reports of each phase, describing the approaches, the people
in charge and general observations. Choices and procedures within each phase
were speciﬁc for each CGC, and generally depended on internal organization,
experience and expertize, and available laboratory, as well as bioinformatics
infrastructure. Each CGC completed the diagnostic trajectory for the nine
patients by providing a full diagnostic report for each patient, stating the
identiﬁed causal variant (if present), other clinically relevant variants and
suggestions for further testing.
For practical reasons, the individual patients were not seen by any of the
clinical geneticists. Instead, we provided all CGCs with full (anonymized)
medical records of all patients.
Patients. The patients had previously undergone genetic diagnostics for
cardiomyopathy using traditional diagnostic methods. Causative mutations
were identiﬁed and reported, but this was not disclosed to the receiving centers.
DNA and appropriate consent were available for each patient, as well as overall
approval of the medical ethics committee of the Academic Medical Center,
Amsterdam, The Netherlands, for this multicenter trial. Whereas not speciﬁed
beforehand, the genetic background of the patients was presumed not to be
complex; causal nucleotide substitutions or indels in well-known cardiomyo-
pathy genes were the cause of disease in all patients with a positive diagnosis.
Full medical records – anonymised − for all patients were shared with all
centers, containing family history, electrocardiogram results, previous tests and
other relevant information.
DNA samples
DNA for all samples was centrally isolated by a single technician (to limit
manipulation bias) from blood-derived cell lines and diluted to 500 ng/ul.
Samples were split and a total of 10 μg of each sample was sent to every center.
Individual 10 μg-portions were sent out to each center; 90 samples in total (the
laboratories that applied an additional outsourcing strategy received two sets).
From there, the individual laboratories started their internal diagnostic
procedure. This procedure deviates slightly from routine diagnostics, where
centers generally receive whole-blood samples for genetic testing. Initially, the
underlying motivation for this approach was purely pragmatic – drawing 10
tubes of whole blood from each patient would be very invasive. However, in the
context of the main objective of CARDIO – to identify new challenges
associated with NGS-based diagnostics – one could take a broader perspective,
and consider this set up a proxy for dealing with diagnostic requests from
outside the own institute. Samples were not recognized (taken up) by all
diagnostic centers and incorporated in the main ﬂow as external requests, but
rather considered as research samples.
Data analysis
The data obtained from the sequencing platforms were initially analyzed
according to the available pipelines within the individual centers.
In the second phase, all data were centrally collected and annotated by ﬁve
different annotation tools; commercial packages from Cartagenia (Leuven,
Belgium), Ingenuity (Qiagen, Redwood City, CA, USA) and SoftGenetics (State
College, PA, USA), and in-house developed tools from CGCs 4 and 8.
Data were submitted to the Leiden Open Variant Database (LOVD), under
the following accession links: http://databases.lovd.nl/shared/individuals/
Patient 1: 00016140
Patient 2: 00016141
Patient 3: 00016142
Patient 4: 00016143
Patient 5: 00016144
Patient 6: 00016145
Patient 7: 00016146
Patient 8: 00016147
Patient 9: 00016148
Informed consent forms
All laboratories provided additional information on their local informed
consent procedures. As these procedures could not be simulated (the
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laboratories only received DNA and medical records; they did not see patients
themselves), the laboratories responded to hypothetical questions on the
consent that would be required from the patients in a routine setting. In a
pre-sequencing report, the laboratories indicated whether or not they would
have the patient's signed consent for the NGS-based diagnostic test that they
were about to perform.
RESULTS
Following the objective of this study − to analyze the choices that
each CGC made to reach a genetic diagnosis for nine patients − the
results do not comprise a performance comparison of sequencing
platforms or bioinformatics pipelines based on technical parameters.
Moreover, all patients had already received a deﬁnite diagnosis, and
therefore the nature and type of mutations identiﬁed are irrelevant in
the context of this study. Instead, the results focus on the collected
information that reﬂects the considerations for the interpretation and
reporting of variants − including personal communication. On the
basis of the collected quantitative and qualitative data we identiﬁed
critical issues and challenges for future diagnostic genome care.
The centers were completely autonomous in their choices for
sample intake, sequencing approach, data analysis and clinical inter-
pretation, which resulted in a wide routing spectrum for the patient
samples across centers (Figure 1). Critical choices in each phase of the
diagnostic process – intake, sequencing, data analysis and interpreta-
tion, and reporting − determined the route in each center.
Sequencing approach
The choice for a particular sequencing approach generally depended
on the available in-house infrastructure within each center. CGCs 1
and 2 both applied an ‘outsourcing’ strategy; they outsourced part of
the diagnostic trajectory to a service provider as an addition to their
in-house strategies. CGC 1 treated the ‘in-house’ and ‘outsourcing’
approaches as separate trajectories, that is enrichment, sequencing and
primary data analysis were done independently in-house (Figure 1;
CGC1a) and at the service provider (CGC1b). Downstream analysis
and interpretation were done in-house for both trajectories, according
to the NEN-ISO 15189/CCKL accreditation guidelines. CGC 2 only
outsourced the sample preparation step and subsequently combined
the corresponding in-house and outsourced samples for whole-
genome sequencing (WGS; because of budgetary restrictions).
Therefore the outsourcing strategy of CGC 2 was rather an internal-
technical diagnostic validation strategy, and was considered as a single
strategy for the rest of the study. The study thus comprised nine
distinct combinations of enrichment protocols and sequencing plat-
forms (Table 1); four cardiomyopathy-targeted gene panels (23− 48
genes; CGCs 4, 6, 7 and 8), one array-based panel of 655 diagnostically
interpretable genes (CGC 1), three whole-exome sequencing (WES)
approaches (CGCs 1b, 3 and 5) and one WGS approach (CGC 2).
Overall, we observed a 10−20 times average coverage difference (30–
500x) between the various approaches (Supplementary Table 1).
Because our objective was not to compare platforms, we did not
collect other parameters, such as coverage per target base and non-
covered target bases.
Data analyses and interpretation
The subsequent phase − data analysis − revealed two main sources of
variation. First, the number of genes included in the analysis panel
varied considerably among centers, ranging from 23 to 48 (Table 1
and Supplementary Table 2). We set no prior criteria for the genes to
be included in the analysis, nor for the type of variants to be
considered. CGCs applying broad-enrichment or WGS approaches
(CGCs 1, 2, 3 and 5) all restricted their analyses to existing panels of
cardiomyopathy-related genes, provided to them by one of the other
centers. This is in accordance with existing informed consent
procedures, which are based on a policy of non-active screening for
variants unrelated to the disease (unsolicited ﬁndings). Whereas the
average number of (identiﬁed) variants per patient ranged from 1315
Figure 1 Overview of the diagnostic process. The diagnostic process of nine samples with cardiomyopathies varied substantially among CGCs. Each colored
line represents the process the nine patients went through in a particular CGC. The ‘metro stops’ represent choices that the various CGCs made in the intake,
sequencing, analysis and reporting phase.
NGS-based genome diagnostics implementation
T Vrijenhoek et al
1144
European Journal of Human Genetics
to 4.2 million, the diagnostic interpretation was restricted to the ± 50
variants implicated in cardiomyopathy.
Second, there was considerable variety in the tools that were used
for analysis and primary interpretation of the data. To reduce the
number of variants to manageable proportions (up to 500 000-fold
reductions), the CGCs used custom in-house analysis pipelines (CGCs
2 and 7), commercially available software packages (CGCs 6 and 8),
or a combination of both (CGCs 1, 3, 4 and 5; Table 1). As a
consequence, there was a wide variety in resulting ﬁle formats for
mapped, called and annotated data. This became especially relevant
when we set out to perform a coordinated analysis of all data from this
study. Even ﬁles that appeared in a 'standard' format (like .BAM or
.VCF) had center-speciﬁc content, which required extensive reformat-
ting for inclusion in the central analysis.
Central collection of all data required repeated requests and
depended much on the willingness of individuals to upload data,
indicating that most centers are not optimally set up for sharing
data. Owing to its total size (±1.5 TB), the ﬁles from CGC 2
(whole-genome data) were transferred via an external hard-drive,
instead of an upload to a central server. Eventually, we collected
all data in workable formats, and performed two subsequent
studies:
A proof-of-concept to explore possibilities for using centralised
data infrastructure. CGC 2 and CGC 6 set up a collaboration with
the Dutch Health Hub (www.dutchhealthhub.nl) to test its storage,
analysis and sharing capabilities. On the basis of the proof-of-
concept study we identiﬁed two important challenges. First,
centralizing data infrastructure requires cooperation of many
people within the individual organizations. Second, doing the two
phases in parallel – technical development and scientiﬁc imple-
mentation – results in miscommunication and requires strict
management of expectations.
A proof-of-principle on three commercially available data analysis
packages. We tested the capacities of three off-the-shelf software
packages – Bench Lab NGS (Cartagenia; www.cartagenia.com),
Table 1 Overview of the sequencing approach of the participating laboratories
CGC
1a Sequencing approach (655 genes) Solid 4 + Agilent LabarrayDx (custom SureSelect)
Analysis (26 genes) BWA/in-house → Alamut/Annovar/Cartagenia
1b Sequencing approach (exome) HiSeq 2000 + Nimblegen SeqCap EZ Human Exome Library v3.0
Analysis (26 genes) CLC → Alamut/Annovar/Cartagenia
2 Sequencing approach (genome) HiSeq 2000 + None
Analysis (24 genes) Stampy/SAMtools → SeattleSeq/Cartagenia
3 Sequencing approach (exome) Solid 4 + Agilent SureSelect Exome v4
Analysis (24 genes) LifeScope → In-house GUI
4 Sequencing approach (23 genes) 454 + Nimblegen Custom 385K
Analysis (23 genes) gsMapper → Manual
5 Sequencing approach (exome) HiSeq 2000 + Nimblegen SeqCap EZ Human Exome Library v3.0
Analysis (23 genes) BWA/SAMtools → Alamut/Annovar
6 Sequencing approach (46 genes) MiSeq + Agilent eArray SureSelect
Analysis (46 genes) SeqNext → SeqNext
7 Sequencing approach (34 genes) 454 + Custom Long-Range PCR
Analysis (34 genes) gsMapper/NEWBLER → In-house
8 Sequencing approach (48 genes) MiSeq + Agilent SureSelect MP Capture Library
Analysis (48 genes) NextGENE → Cartagenia/Alamut
See Supplementary Table 2 for full description of the gene panels for the analysis.
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Variant Analysis (Ingenuity; www.ingenuity.com) and Geneticist
Assistant (Softgenetics/BioKé; www.softgenetics.com) – to consis-
tently analyze data and ﬁlter variants. All packages consistently
identiﬁed the 8 causal variants in all data sets, but the number of
variants included as clinically signiﬁcant differed between the
various tools. Further in-depth analysis on the nature of these
differences was not performed as this is beyond the scope of
this study.
Diagnoses
Despite the variety in approach and analyses, the primary molecular
diagnoses – as indicated in the diagnostic letters that would in normal
practice be sent to the responsible clinician – were largely consistent
over the eight centers. Patient 9 formed an exception to this
consistency, for which six CGCs reported a causal mutation in
MYBPC3 (Table 2). This MYBPC3 mutation was not identiﬁed by
CGC 1 and CGC 8, owing to low sequence coverage in the exon 26
region of this gene, where the mutation was located. The subsequent
interpretation and diagnosis for patient 9 differed considerably
between these two centers. CGC 8 – a center for which cardiomyo-
pathy diagnostics is a key strategy program – reported to have found
‘no causal variant’ in patient 9. CGC 8 thus provided an under-
diagnosis based on the NGS results. Conversely, CGC 1 – with less
focus on diagnosis of cardiomyopathies – reported that ‘the diagnosis
of Fabry disease’ was conﬁrmed in patient 9, based on the detection of
another mutation in GLA. This center thus provided an alternative
diagnosis for patient 9.
Notably, only CGCs 1, 4 and 7 conﬁrmed all reported mutations by
Sanger sequencing; the other centers indicated they would do so in a
routine diagnostic setting before reporting. Some centers would also
apply additional Sanger-based amplicon sequencing in routine diag-
nostics, to ﬁll any potential gaps that their NGS-based approach may
leave. After collection of the results from all centers, but before
disclosing the expected results, CGC 8 applied such gap-ﬁlling
approach in a second stage and indeed identiﬁed the causal mutation
in MYBPC3 of patient 9.
For patient 4, only CGC 7 reported a causal mutation in MYH7; all
other centers did identify the mutation in this gene, but did not report
it as causal. Despite the absence of a deﬁnite diagnosis, the CGCs that
applied a broad sequencing approach did not expand their analyses
beyond the known cardiomyopathy genes for this patient.
In addition to the causal variants (Table 2), seven of the eight
centers reported variants of unknown signiﬁcance (VUSs) in their
diagnostic letters (Supplementary Table 3). No two centers provided
identical reports for all patients. The largest source of variation is the
inclusion or exclusion of TTN40 in the analysis panel. CGCs 6 and 8
include TTN in their routine-analysis pipeline, and thus reported in
total 11 and 10 VUSs for this gene, respectively (Supplementary Table
4). The reports of the centers that reported VUSs were largely
consistent for patients 2, 4 and 9.
The contribution of different experts
In addition to the ﬁnal diagnostic outcomes, we also considered the
process that led to the diagnosis, and the people involved. Within each
CGC, responsibility − throughout the procedure − was given to
three to ﬁve different people (Table 3). The study coordinator only
communicated with a single local-contact person per CGC; the latter
was responsible for the intake and further processing of the samples
and medical records within his or her CGC. Two observations can be
made from the reports. First, the CGCs varied considerably in the
people that were involved in each phase (Figure 1 and Table 3). For
example, clinical geneticists, laboratory specialists, cardiologists or a
combination of these evaluated the medical records. The choice for a
certain sequencing and analysis approach was irrespective of disease
subtype or expected genetic complexity of the individual patients. This
is inherent to the set up of the study and how it was perceived, but it
also indicates the connections between clinic, laboratory and research.
CGCs 4, 6 and 8 brought the medical records into a multidisciplinary
meeting (in which lab specialists, clinical geneticists and cardiologists
discuss individual patients). CGCs 3 and 5 kept the medical records
within the laboratory, and the contacts of the other centers auto-
matically forwarded the records to the clinical geneticist, without
speciﬁc request (Table 3). CGC 7 did not have the need to involve a
multidisciplinary meeting for their diagnostics because of their
experience in cardiomyopathy diagnosis.
In the data analysis phase, six of eight CGCs involved a bioinfor-
matician to analyze the data, and in ﬁve CGCs this bioinformatician
was speciﬁcally appointed within the diagnostic unit. In practice,
however, most of them work in a research environment, to develop
pipelines and adapt them to novel technologies, as well as diagnostic
needs. The bioinformatics experts thus work on both sides of the
traditional divide between diagnostic care and genetic research.
To obtain insight in the consent procedures in each CGC, we
collected the forms that each CGC would normally use to obtain
consent from patients to undergo NGS-based diagnostics. In subse-
quent interviews, we obtained additional information on the applica-
tion of a particular consent procedure. We found that informed
consent procedures in all CGCs are generally adequate for diagnostic
NGS applications that target a limited set of genes (CGCs 1, 4, 6, 7 and
8; Table 4). Where appropriate, the consent forms contained
information on the approach taken, on unsolicited ﬁndings and
Table 2 Diagnosis for 9 CARDIO patientsa
Patient CGC 1 CGC 2 CGC 3 CGC 4 CGC 5 CGC 6 CGC 7 CGC 8
1 TNNI3 TNNI3 TNNI3 TNNI3 TNNI3 TNNI3 TNNI3 TNNI3
2 MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3
3 MYH7 MYH7 MYH7 MYH7 MYH7 MYH7 MYH7 MYH7
4 − − − − − − MYH7 −
5 LMNA LMNA LMNA LMNA LMNA LMNA LMNA NA
6 MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3
7 MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3
8 PLN PLN PLN PLN PLN PLN PLN PLN
9 GLA MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3 MYBPC3 −
aEach center independently provided a diagnosis for each patient based on the most likely gene mutation. The table cells indicate in which gene the particular center identiﬁed the causal variant
for the corresponding patient. Discordant diagnoses are indicated in bold. Only one center reported a causal mutation for patient 4. NA, not assessed; ‘− ‘, no causal variant reported.
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actions in diagnostic and research contexts. Conversely, the available
consent procedures for exome and genome sequencing (CGCs 2, 3
and 5) generated debate across centers. In total we identiﬁed seven
characteristics that are important in providing comprehensive infor-
mation to patients (Table 4).
Subsequent to gathering data from all CGCs, we organized a series
of workshops with representatives from all the participating centers, to
discuss the various strategies used in the participating centers, and
aimed at obtaining consensus at a single strategy. Main conclusions
from these workshops were:
The classical divide between research and diagnostics is becoming
more blurred when using NGS. To control responsible integration of
research and diagnostics, CGCs should develop a framework that
manages data access responsibly, i.e. respecting the rights of patients
and optimal care, while not hampering research needed to obtain
answers to the questions of these same patients and families.
Analysis of limited gene panels (regardless of the sequencing
approach) can generally be done under existing consent procedures
and is essentially not different from evaluation of genes using
traditional Sanger sequencing. For broader analysis using untargeted
analysis of NGS results (eg screening for de novo mutations in WES/
WGS data) patients should be speciﬁcally counseled, and be asked to
consent speciﬁcally for this procedure (including the risk for
unsolicited ﬁndings).
DISCUSSION
The results of our study highlight some of the challenges that the
‘genetics clinic of the future’ faces. CGCs across the Netherlands
obtained largely consistent NGS-based diagnoses for nine patients,
even without prior standardization or detailed prior agreements.
Nevertheless, the centers were faced with a number of choices that
become increasingly important for high-quality clinical genomic care.
Some of these are well-known and have been discussed extensively,
such as increasing data volumes, informed consent procedures and
identiﬁcation of variants with unknown clinical relevance.17,25,26,28,30,41
In our study we focused on the less-obvious challenges: interpreting
and reporting genetic variants, incorporating multidimensional diag-
noses and deﬁning roles and responsibilities in the genetics clinic of the
future.
The interpretation challenge
Diagnoses were consistent across centers for all but patient 9. For this
patient, six centers identiﬁed a pathogenic MYBPC3 mutation, and
provided a diagnosis of ‘hypertrophic cardiomyopathy’. Conversely,
CGC 1 and 8 failed to identify the MYBPC3 mutation by their
sequencing approach, and reported a diagnosis of ‘Fabry’s disease’, and
a negative diagnosis, respectively. The central conclusion from this
observation is not that CGC 1 and CGC 8 provide lower quality
sequencing than the other centers. Rather, it is more interesting to
consider the implicit implementation choices that reﬂect the difference
in diagnostic outcome. Like CGC 1 and 8 in our study, many CGCs
apply complementary Sanger-based sequencing in a routine diagnostic
setting to assure sufﬁcient coverage for all relevant regions. Indeed,
after the NGS-based results were collected, CGC 8 ‘closed the gaps’
and conﬁrmed the presence of the MYBPC3 mutation. The necessity
to apply such ‘closing-the-gaps' strategy may reﬂect the phase of
evolution that NGS-based diagnostics is currently going through,39 but
it is unlikely to be sustainable for future purposes. As the number of
Table 4 Informed consent elementsa
CGC
Sequencing approach
(targeted or broad)
Distinction
diagnostics − research Information sheet
Distinction
minors − adults Unsolicited ﬁndings
Option
‘right-not-to-know’
1 Yes Yes Yes No Yes Yes
2 Yes No Yes No Yes No
3 Yes No Yes No Yes No
4 Yes Yes No Yes No No
5 Yes No Yes No Yes No
6 Yes Yes Yes No Yes No
7 Yes Yes No Yes No No
8 Yes Yes No Yes No No
aOverview of the elements mentioned (‘yes’) and not mentioned (‘no’) in the informed consent forms of the various centers. Note, the informed consent procedures were under considerable debate
during this study, and may thus have changed accordingly.
Table 3 Responsibles for various aspects of diagnostic process
Main contact Medical record Sequencing, including sample prep Data analysis, including ﬁltering Interpretation and reporta Counselingb
CGC1 LAB CLINGEN LAB BOINF (diagnostics) LAB NA
CGC2 Postdoc CLINGEN Sequencing facility BOINF (research) LAB and CLINGEN NA
CGC3 LAB LAB LAB BOINF (diagnostics) CLINGEN NA
CGC4 LAB Multidisciplinary meeting LAB LAB LAB and CLINGEN NA
CGC5 LAB LAB LAB BOINF (diagnostics) LAB CARDIO
CGC6 LAB Multidisciplinary meeting Sequencing facility LAB LAB NA
CGC7 LAB LAB and CLINGEN LAB BOINF (diagnostics) LAB NA
CGC8 LAB Multidisciplinary meeting LAB BOINF (diagnostics) LAB NA
Abbreviations: BIOINF, bioinformatician; CARDIO, cardiologist; CLINGEN, clinical geneticist; LAB, laboratory specialist clinical genetics; NA, not assessed.
aThis involves the selection of causal variants and relevant variants of unknown signiﬁcance to be reported back to the referring specialists. Reports (also referred to as ‘outcome letters’) comprise
full interpretation of all variants reported.
bCounseling was not literally done as a part of this study, but CGC 5 provided a summary of the counseling that would be done for each patient.
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patients and disease types that apply for NGS-based diagnostics
increases, Sanger-based complementation may put a disproportionate
burden on time and budget of individual CGCs. There is thus an
urgent need to develop strategies that are not dependent on additional
Sanger sequencing. This may even hold for applying Sanger sequen-
cing for validation purposes, although this aspect was not considered
in our study. Of note, the MYBPC3 mutation was present in the
exome data from the outsourcing trajectory (CGC1b), but as the latter
was considered a research setting, CGC 1 did not include this in the
diagnostic report.
In addition to various sequencing outcomes, we observed sub-
stantial differences in interpretation of similar sequencing outcomes.
For example, the CGCs varied substantially in their judgment on the
contribution of the GLA variant to the disease in patient 9. Apart from
CGC 1, four other centers (CGCs 4–7) observed the GLA variant, but
these all classiﬁed it as ‘variant of unknown signiﬁcance’ (VUS). The
origin of such interpretation differences is hard to retrieve. One
possible explanation may stem from variation in bioinformatic
approaches. Many factors – in-house experience, literature, population
frequencies, clinical ﬁndings, public and in-house databases – may
determine how variants are prioritized. Moreover, experience with
interpreting particular variants (eg, in the GLA gene) may determine
the diagnostic outcome. Whereas all centers generally follow the same
best practice guidelines on ‘Unclassiﬁed Variants’ and ‘Next Genera-
tion Sequencing’ (Clinical Molecular Genetics Society), these cannot
assure absolute consistency among centers. Another explanation may
be that the diagnosis for this patient is more complex than originally
thought. Compound genetic effects are known to occur, especially in
cardiomyopathies, so they could have had a role in this particular
patient.42,43 Indeed, CGC 7 speculated on a possible compound
genetic effect of the GLA variant in addition to the causal MYBPC3
mutation, but could not report this with certainty.
From these results it becomes clear that the main challenge for
interpreting and reporting variants is not in the technology. Rather,
meeting the interpretation challenge requires a number of non-
technological issues to be solved. First, interpretation could be
signiﬁcantly improved by sophisticated and transparent exchange of
variants associated with clinical indications. Several databases exist that
document clinical variation, such as the Human Gene Mutation
Database (HGMD), ClinVar and the LOVD,44,45 and managed data
access models are being developed.46 However, the strict divide
between diagnostic care and research seriously hampers effective data
exchange. Whereas many foresee a blurring of boundaries between
research, clinic and society, the ethical and legal issues are of major
concern.46,47 An inherent requirement for data exchange is the
harmonization of data formats. The different approaches of the CGCs
resulted in a variety of data ﬁle formats that could not be automatically
exchanged. Central analysis of data from all CGCs required substantial
ﬁle conversion, whereas accepting that some information (eg second
allele information) could not be retrieved. Data-ﬁle validation by
format validation tools may reduce the heterogeneity, making data
sharing and sustainable archiving easier.
Second, assessment of the effect of individual variants is only useful
if they are considered in their biological context. Many centers use
recurrence in patients with similar phenotypes as clinical validation,
whereas application of functional assays – preferably in a diagnostic
context – would be more appropriate for comprehensive interpreta-
tion. NGS technologies have considerably increased the number of
variants that are being detected in a person’s genome, but the
(putative) function for most of these remains largely unknown.48,49
In silico functional prediction programs are widely available,50,51 but
the nuances that are inherent to any algorithm and the lack of
standards are difﬁcult to work with in a clinical context.25 Functional
assays and allele- and/or gene-speciﬁc animal models do already exist
for a small subset of disorders (eg, metabolic, mitochondrial and
congenital disorders).52,53 However, most clinical laboratories cannot
easily incorporate such tests, as they are expensive, labor intensive,
difﬁcult to standardize and automate, challenging to interpret, time-
consuming and outside the scope of existing regulatory guidelines.
Incorporating functional annotation into routine clinical interpreta-
tion of results thus requires stronger ties between clinical testing and
functional modeling laboratories, consensus guidelines for functional
modeling, and introduction of functionally annotated variants into
electronic medical records of patients.
Finally, there is a clear need for extensive clinical phenotyping of
patients.54 In our study, we provided all centers with full medical
records for all nine patients. Two centers (CGCs 1 and 2) actually used
these in pre-test clinical assessment, but none of the centers adapted
their sequencing and analysis strategy according to the information in
the medical records. Instead, the medical records were mostly used for
interpretation after testing. This may be partly inherent to the set up of
our study, but it may also reﬂect that the inclusion of clinical features
is shifting from the front of the diagnostic process, to the end.
A ‘genetic diagnosis’ has many dimensions
Before the introduction of NGS, there was broad consensus on what
was to be considered a ‘genetic diagnosis’. It referred to the outcome
of genetic testing in a symptomatic individual, and could be either
positive (‘we found a cause for disease’) or negative (‘no variant’), with
an occasional ‘variant of unknown signiﬁcance’ (VUS). Alternative
diagnoses – in addition to underdiagnoses – go beyond what is
traditionally considered ‘a genetic diagnosis’. What a genetic diagnosis
may be in the future – a multidimensional and non-static outcome of
a genetic testing procedure – is currently not so often taken into
account in the implementation of NGS in routine diagnostics.
Alternative diagnoses may impose many issues, of which ‘greedy
interpretation’ may be particularly challenging. As we observed for the
diagnosis of patient 9, there may be a certain level of greediness to ﬁnd
a genetic cause for disease, especially in cases where known disease
genes provide no deﬁnite answer. This is also the primary motivation
for broad interrogation of exomes or genomes of patients for which
diagnosis remains unclear. Despite the negative diagnosis for patient 4,
none of the centers applying exome- and genome-wide approaches
‘opened up’ the exome or genome for this patient. This may have be
owing to the impossibility to do a trio-analysis, which is generally
required for relevant interpretation of variants. Also, the appropriate
consent for performing exome- or genome-wide analysis may have
been lacking, or it may have been unclear which consent to follow; the
one that the patients originally signed, or the one that centers generally
apply for NGS-based diagnostics. Fact is, that exome- or genome-wide
analyses increase the number of potential disease-related variants,
which may further induce greediness in interpreting the data. Such
level of greediness is necessary to provide the highest quality of
genome care, but there is thus far no obvious strategy available for
controlling it.
The widespread implementation of NGS in routine diagnostics adds
new dimensions to the concept of ‘genetic diagnosis’. Especially in the
context of interrogating whole exomes or even whole genomes, and
with increasing knowledge about the effect of genomic variation,
identifying the multiple dimensions of a genetic diagnosis becomes
urgent, especially if other variants than those related to the clinical
phenotype are to be considered as part of comprehensive diagnosis.55
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Positions and responsibilities in diagnostic genome care
Our results do not only show the effect of NGS on the diagnostic
outcome, but also on the organization of diagnostic genome care in its
entirety. It is expected that the absolute number of requests for NGS-
based testing in classical diagnostic disease areas will increase
signiﬁcantly.17 Moreover, there is an ongoing broadening of genes
and disease areas that are eligible for diagnostic testing.18 Obtaining a
high-quality diagnosis can thus no longer be the sole responsibility of
clinical geneticists, but requires intensive interaction between labora-
tory specialists, clinical geneticists, other medical specialists and
bioinformaticians/data analists. Especially the latter have become
crucial; building the appropriate analysis pipelines and assuring the
quality and versioning of the tools is in their hands. Primary caretakers
and laboratory specialists typically have to trust the judgment of
bioinformaticians on certain relevant details, often without full
comprehension. Whereas trusting (appropriately validated and certi-
ﬁed) ‘black boxes’ is not a new phenomenon in the diagnostic context
– capillary sequencing similarly comprised automated analysis and
visualization steps – the appreciation of bioinformatics knowledge may
be exemplary for the changing context in which data analysis occurs.
These developments also raise questions about the information ﬂow
between patient, treating physician and testing laboratory. Until
recently, information exchange has been asymmetrical. Whereas
models for ‘shared decision making’ have been in practice for many
years, the inherent complexity of genetic information makes supplying
it a largely paternalistic undertaking.56 Moreover, diagnostic reports
are typically textual documents – and thus based on fractional and
point-in-time data, ill-suited for computer-based decision support.57
Implementation and use of electronic health records, the call for
sharing data from both funders and patients, and the increasing public
interest in genetic services warrants novel approaches to dynamic and
automated reporting of genomic knowledge.58–62
Finally, our results further contribute to the obvious challenges of
NGS-based diagnostics. Regardless of costs and throughput of
sequencing (which are generally expected to be overcome sooner or
later), NGS requires substantial investments in data infrastructure,63
and likely expands the working ﬁeld of diagnostics. Whereas our
ability to interpret genomic data does not instantly improve with NGS
– the biology remains complex – the ability to observe the entire
genome at ultimate nucleotide resolution with predeﬁned hypotheses
on pathogenic origin opens up powerful new clinical opportunities. In
addition to efﬁcient continuation of traditional diagnostics, NGS
proves very effective in providing diagnosis for previously unsolved
rare cases 9,64 and in supporting appropriate treatment.65 For instance,
clinical information from medical records previously determined
which genes should be (individually) tested for and in which order;
now it mainly serves to correctly ﬁlter and interpret genetic variants.
Obviously, this may also affect professional roles in relation to genetic
care;66,67 genetic testing can be expected to be requested much more
often as these increasingly contribute to clinical diagnosis and decision
making.
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